Skip to main content
Aclaris bosakitug misses both endpoints in 109-patient trial
Image for illustrative purposes only. Not a real photo.

Aclaris bosakitug misses both endpoints in 109-patient trial

By

Key points

  • Aclaris Therapeutics (NASDAQ:ACRS) reported that its Phase 2 ADMIRATION trial of bosakitug failed to meet its primary and secondary endpoints in moderate-to-severe atopic dermatitis.
  • Aclaris shares last closed at $3.92 on November 13, down 2.00% before the November 16 announcement.
  • The company is shifting its development focus toward oral kinase inhibitors, ATI-052 and other pipeline candidates, with several clinical and regulatory milestones planned for 2026 and 2027.

Aclaris Therapeutics (NASDAQ:ACRS) reported that its Phase 2 ADMIRATION trial of bosakitug failed to meet its primary and secondary endpoints in patients with moderate-to-severe atopic dermatitis.

The randomized, placebo-controlled trial enrolled 109 patients, with its primary endpoint measuring the percentage change in Eczema Area and Severity Index (EASI) score from baseline at week 24.

"We are disappointed that the ADMIRATION trial did not overcome the historical challenges of addressing atopic dermatitis with an anti-TSLP monoclonal antibody alone," said Aclaris Chief Executive Officer Dr. Neal Walker.

Despite missing both endpoints, bosakitug demonstrated TSLP target engagement and reduced biomarkers associated with Th1, Th2 and Th17 immune activation, while the treatment was generally well tolerated.

Aclaris said its development priorities remain focused on oral kinase inhibitors and ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, and confirmed that its Phase 2b modzatinib trial in lichen planus has started.

The company has completed investigational new drug (IND)-enabling studies for ATI-9494 and expects to file its application in the fourth quarter of 2026, while it intends to start a Phase 2b ATI-052 trial in eosinophilic esophagitis in the first quarter of 2027.


Frequently asked questions